Access Program Information
The primary objective of the study is:
• To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate
therapy until the product becomes commercially available.
The secondary objective of the study is:
• To assess the long-term safety of amifampridine phosphate in patients with
LEMS/CMS/downbeat nystagmus